There is no registration fee for this event. However, preregistration is advised as seating is limited for the in-person meeting in Las Vegas. See LOCATION tab for instructions on how to secure hotel accommodations.

---

 

This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Daiichi Sankyo Inc, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, R-Pharm US, Seagen Inc, and Taiho Oncology Inc.

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to:

Lymphoma

• Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
• Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory (R/R) Hodgkin lymphoma.
• Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
• Consider patient age, performance status and other clinical and biological factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor (CAR) T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients about the potential benefits of this therapeutic strategy.
• Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in clinical management.
• Recall new data with agents and strategies currently under investigation for various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

Urothelial Bladder Cancer and Renal Cell Carcinoma

• Review available clinical trial results with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic urothelial bladder cancer (UBC), and determine the current utility of these agents in clinical practice.
• Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom these approaches would be appropriate.
• Effectively apply evidence-based research and other clinical and biological factors in the best-practice selection of first-line therapy for patients with metastatic renal cell carcinoma (RCC).
• Develop a rational approach to the selection and sequencing of systemic therapies for patients with metastatic RCC who experience disease progression on first-line treatment.
• Consider available data supporting the use of anti-PD-1 antibody therapy for nonmetastatic UBC and RCC, and determine how this strategy can be appropriately integrated into patient care.
• Reflect on available and emerging data with investigational agents and strategies currently in testing for UBC and RCC, and appropriately refer patients for clinical trial participation.

Hepatobiliary and Pancreatic Cancers

• Consider age, performance status, degree of liver function and other clinical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
• Evaluate available data documenting the efficacy and safety of anti-PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers (BTCs), and consider the clinical role of this strategy.
• Recognize the molecular heterogeneity of cholangiocarcinoma and other BTCs, and appreciate the biological rationale for efforts to exploit documented alterations in patients with these diseases.
• Recall clinical trial data with approved and investigational systemic interventions for patients with metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to selecting therapy.
• Appraise available and emerging data with investigational agents currently in testing for pancreatic and hepatobiliary cancers, and appropriately refer patients for clinical trial participation.

Gynecologic Cancers

• Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for newly diagnosed and recurrent ovarian cancer (OC), and use this information to optimally incorporate these agents into patient care.
• Appreciate the biological rationale for and published and emerging clinical research data with PARP inhibitors in combination with other systemic therapies, and consider the current and potential implications for OC management.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal testing methods and the current role of novel approaches to therapeutically exploit this newly relevant biomarker.
• Review the benefits observed with anti-PD-1/PD-L1 antibodies for advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer (EC), and appropriately integrate these agents into patient care.
• Consider the biological rationale for and available and emerging data with the combination of anti-PD-1/PD-L1 antibodies with chemotherapy and/or other systemic agents, and select patients with advanced EC for treatment with these novel regimens.
• Comprehend published efficacy and safety findings with anti-PD-1 antibodies as monotherapy or in combination with chemotherapy with and without anti-VEGF therapy for metastatic cervical cancer (CC), and consider the current and potential clinical role of immune checkpoint inhibition.
• Recognize the incidence of tissue factor expression in patients with CC, and evaluate the current and future role of novel agents designed to exploit this therapeutic target.
• Reflect on investigational agents and strategies currently in testing for OC, EC and CC, and appropriately refer patients for clinical trial participation.

Multiple Myeloma

• Customize the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM), considering new clinical research findings, patient- and disease-related factors — including cytogenetic profile — and fitness for stem cell transplantation.
• Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
• Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with R/R MM.
• Understand the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies in order to facilitate their integration into MM management algorithms.
• Evaluate the biological rationale for the use of CAR T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted strategy for MM, and identify patients for whom this novel approach should be considered or recommended.
• Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and select patients for whom treatment with or a clinical trial of one of these novel agents would be appropriate.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

HER2-Positive and Triple-Negative Breast Cancer

• Evaluate recently presented clinical research findings to determine their effect on the current management of localized or metastatic HER2-positive or triple-negative breast cancer.
• Use published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
• Review published clinical trial data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies and PARP inhibitors for patients with localized or metastatic triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
• Implement a long-term clinical care plan for patients with metastatic HER2-positive breast cancer, incorporating current and recently approved anti-HER2 therapies.
• Evaluate published research guiding the selection and sequencing of available therapeutic agents for patients with metastatic TNBC.
• Appreciate the incidence, characteristics and clinical relevance of HER2-low metastatic breast cancer, and understand available disease-management approaches.
• Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and strategies under development for localized and metastatic HER2-positive or triple-negative breast cancer.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A CME credit form will be given to each participant at the conclusion of the activity

NCPD Credit Designation Statements
This educational activity for 6 contact hours is provided by Research To Practice.

This activity is awarded 6 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A Credit Form link will be emailed to participating nurses within 3 business days of the activity.

ONCC/ILNA Certification Information
This program will be submitted for ONCC/ILNA certification.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 6 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer and an external, independent nurse reviewer, for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided prior to the activity.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Daiichi Sankyo Inc, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, R-Pharm US, Seagen Inc, and Taiho Oncology Inc.

Bellagio Las Vegas
3600 S Las Vegas Blvd
Las Vegas, NV 89109
Hotel Phone: (888) 987-6667

Meeting Room
Raphael Ballroom – First Floor

Hotel Room Reservations

• American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
• Room reservation information will be included with the confirmation email after you have registered for this program.

Directions
The Bellagio Las Vegas hotel is the main venue for the 2023 AON Clinical Summit.